Antibacterial Alternatives to a Dying Antibiotic Pipeline

Purpose of review This study summarized the current problems and potential solutions related to the rise of multidrug-resistant bacteria, the lack of antibiotics, and new avenues of research in developing new antimicrobial alternatives, such as using bacteriocins, bacteriophage therapy, antimicrobia...

Full description

Saved in:
Bibliographic Details
Published in:Current treatment options in infectious disease 2023, Vol.15 (4), p.61-88
Main Authors: Lorenzo-Leal, Ana C., Bach, Horacio
Format: Article
Language:English
Subjects:
Antibiotics
Antimicrobial agents
Antimicrobial peptides
Bacteria
Bacteriocins
Infectious Diseases
Medicine
Medicine & Public Health
Multidrug resistance
Multidrug resistant organisms
Nanoparticles
Phages
Pharmaceutical industry
R&D
Research & development
Topical Collection on Bacterial Infections
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of review This study summarized the current problems and potential solutions related to the rise of multidrug-resistant bacteria, the lack of antibiotics, and new avenues of research in developing new antimicrobial alternatives, such as using bacteriocins, bacteriophage therapy, antimicrobial peptides, and nanoparticles. Recent findings Advances in the research of alternative antimicrobial agents in emerging with promising results. These alternative antimicrobials are still developing, and more research is required to bring these products to clinical applications. Summary A dramatic increase in the emergence of multidrug-resistant bacteria is challenging the research community to find new antimicrobial agents. Multifactorial events have contributed to this emergence, including the lack of research and development of new antibiotics in pharmaceutical companies, the rise of multidrug-resistant bacteria, and the misuse of antibiotics. Another factor exacerbating this problem is that most pharmaceutical companies have closed their antibiotic discovery pipelines. All these factors contributed to the appearance of more resistant pathogenic bacteria, alarming and burdening the health systems.
ISSN:1534-6250
1523-3820
1534-6250
DOI:10.1007/s40506-023-00267-6